No Data
Mineralys Therapeutics' Lorundrostat Shows Efficacy in NEJM-published Study
Express News | Mineralys Therapeutics Reveals Publication Of Pivotal Phase 2 Advance-HTN Results In The New England Journal Of Medicine
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
Institutional Investors Must Be Pleased After a 8.1% Gain Last Week That Adds to Mineralys Therapeutics, Inc.'s (NASDAQ:MLYS) One-year Returns
New Analyst Forecast: $MLYS Given 'Buy' Rating
Mineralys Therapeutics Insider Sold Shares Worth $879,008, According to a Recent SEC Filing